UroGen Pharma (NASDAQ:URGN) is a specialized biopharmaceutical company focused on developing and commercializing innovative therapies for urological pathologies. The company's main objective is to improve patients' lives by offering new and advanced treatment options for urothelial and urinary tract cancers, among other diseases. UroGen's proprietary technology, RTGel, underpins several of its development projects, aiming to enhance the delivery and efficacy of therapeutics directly to the urinary tract. With a commitment to innovation, UroGen Pharma works on a broad range of projects, from research and development to the commercialization of its products, targeting conditions that have long been underserved by the medical community. The firm is dedicated to pushing the boundaries of urological care, striving to provide breakthrough solutions that can significantly impact patient outcomes.